ResearchPod Summary
This study evaluates the economic return on investment (ROI) of the U.S. FDA's GenomeTrakr program, which uses whole-genome sequencing (WGS) to monitor foodborne pathogens like Salmonella, Listeria, and Shiga toxin-producing Escherichia coli (STEC). Researchers collected detailed operational cost data—including equipment, consumables, and staff labor—from 23 participating federal, state, and academic laboratories over a 12-month period. They then applied an established analytical framework to estimate the number of human illnesses averted by these surveillance activities and the corresponding economic savings in healthcare and societal costs.
The analysis reveals that WGS surveillance is a highly cost-effective public health tool. Across the 36 laboratories studied, the program was estimated to avert 870 illnesses annually, resulting in 286, with higher-throughput laboratories achieving lower per-sample costs due to economies of scale. The overall ROI of 31:1 demonstrates that the financial benefits of preventing foodborne outbreaks significantly outweigh the costs of maintaining the necessary genomic infrastructure.
Foodborne illnesses impose a massive economic burden, estimated to exceed $75 billion annually in the U.S. This study provides a rigorous, data-driven justification for sustained funding of genomic surveillance. By developing a publicly available web-based calculator, the authors enable local and regional partners to independently quantify the value of their own WGS activities. This transparency helps laboratories identify funding gaps, optimize resource allocation, and demonstrate the tangible public health impact of their work to stakeholders.
AI-generated third-party summary by ResearchPod. Not official content or an endorsement by the paper authors or affiliated organizations.